Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.34 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.31 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30003591 | 0.92 | GRM1 (0.42) | NSD2GRM5GRM1TBK1PDK4 | |
| SCHEMBL26894701 | 0.92 | GRM1 (0.42) | NSD2GRM5GRM1TBK1PDK4 | |
| SCHEMBL26697728 | 0.81 | QDPR (0.34) | ALDH1A1 | |
| SCHEMBL26893882 | 0.76 | GRM1 (0.45) | GRM5GRM1GPR119PDK4 | |
| SCHEMBL30003484 | 0.76 | GRM1 (0.45) | GRM5GRM1GPR119PDK4 | |
| SCHEMBL30775561 | 0.72 | L3MBTL1 (0.32) | — | |
| SCHEMBL25352925 | 0.70 | MAP4K4 (0.48) | GPR119 | |
| SCHEMBL30126189 | 0.70 | NSD2 (0.35) | NSD2TLR9GPR119 | |
| SCHEMBL30125949 | 0.70 | NSD2 (0.35) | NSD2TLR9GPR119 | |
| SCHEMBL30478687 | 0.69 | NAMPT (0.45) | GRM5GRM1TBK1GPR119PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037346-B2 | Amino-substituted heteroaryls for treating cancers with EGFR mutations | NUVALENT, INC. (US) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037346-B2 | Amino-substituted heteroaryls for treating cancers with EGFR mutations | EGFR, ERBB2, ERBB3 | NSD2 1962/4885GRM5 1037/4885GRM1 2232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.